NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.5b

Last Updated

2021/05/11 22:20 UTC

Data Sources

Company Financials +

Executive Summary

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. More Details


Snowflake Analysis

Excellent balance sheet with concerning outlook.

Share Price & News

How has C4 Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CCCC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CCCC's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

11.0%

CCCC

-4.8%

US Biotechs

-1.2%

US Market


1 Year Return

n/a

CCCC

19.3%

US Biotechs

48.3%

US Market

Return vs Industry: Insufficient data to determine how CCCC performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how CCCC performed against the US Market.


Shareholder returns

CCCCIndustryMarket
7 Day11.0%-4.8%-1.2%
30 Day8.5%0.9%0.2%
90 Day-23.8%-13.0%1.6%
1 Yearn/a21.1%19.3%50.8%48.3%
3 Yearn/a24.2%17.8%62.0%51.9%
5 Yearn/a50.2%38.5%126.9%101.7%

Long-Term Price Volatility Vs. Market

How volatile is C4 Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is C4 Therapeutics undervalued compared to its fair value and its price relative to the market?

5.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CCCC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CCCC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CCCC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CCCC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CCCC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CCCC is overvalued based on its PB Ratio (5.4x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is C4 Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-13.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCCC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CCCC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CCCC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CCCC's revenue is expected to decline over the next 3 years (-7.9% per year).

High Growth Revenue: CCCC's revenue is forecast to decline over the next 3 years (-7.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CCCC's Return on Equity is forecast to be very high in 3 years time (131.1%).


Past Performance

How has C4 Therapeutics performed over the past 5 years?

-55.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CCCC is currently unprofitable.

Growing Profit Margin: CCCC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CCCC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CCCC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CCCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.5%).


Return on Equity

High ROE: CCCC has a negative Return on Equity (-23.62%), as it is currently unprofitable.


Financial Health

How is C4 Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CCCC's short term assets ($381.0M) exceed its short term liabilities ($43.9M).

Long Term Liabilities: CCCC's short term assets ($381.0M) exceed its long term liabilities ($75.5M).


Debt to Equity History and Analysis

Debt Level: CCCC's debt to equity ratio (3.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CCCC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CCCC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CCCC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 77.3% each year


Dividend

What is C4 Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CCCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CCCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CCCC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CCCC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CCCC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Andrew Hirsch (49 yo)

0.67

Tenure

US$21,267,671

Compensation

Mr. Andrew J. Hirsch is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeutics, Inc s...


CEO Compensation Analysis

Compensation vs Market: Andrew's total compensation ($USD21.27M) is above average for companies of similar size in the US market ($USD3.75M).

Compensation vs Earnings: Insufficient data to compare Andrew's compensation with company performance.


Leadership Team

Experienced Management: CCCC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: CCCC's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: CCCC only recently listed within the past 12 months.


Top Shareholders

Company Information

C4 Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: C4 Therapeutics, Inc.
  • Ticker: CCCC
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.530b
  • Shares outstanding: 43.19m
  • Website: https://www.c4therapeutics.com

Number of Employees


Location

  • C4 Therapeutics, Inc.
  • 490 Arsenal Way
  • Suite 200
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings


Biography

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/11 22:20
End of Day Share Price2021/05/11 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.